<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

Doug Devens

20 years of diverse medical device experience, including leading companies 3M, Coloplast and Boston Scientific, along with emerging companies. Leadership experience in product development, including championing the process for voice of customer and concept feedback sessions with key thought leaders.

Recent Posts

2 min read

Plastic Surgery: The Meeting 2023 in Austin, TX

By Doug Devens on 12/19/23 9:30 AM

SmartTRAK attended key sessions on ADM use and reports on the latest trends impacting the US Breast Matrices Market.

The American Society of Plastic Surgeons (ASPS) and various manufacturers continue to pursue IDEs to gain an indication to use an acellular dermal matrix (ADM) in breast reconstruction. At Plastic Surgery: The Meeting 2023 (PSTM2023), held in Austin, TX, SmartTRAK attended key sessions on ADM use and reports on the latest trends affecting the market for ADMs.

In this article, SmartTRAK discusses the evolution and growth of ADMs and shares observations from the meeting across primarily two sessions covering breast reconstruction: They are:

  • “Support Group: A Mesh For Each Patient and Getting Away Without It”
  • “Back to the Future: Moving Forward or Going Back with Pre and Subpectoral Reconstruction.”

Just click the button below to download and read the complete detailed "Plastic Surgery: The Meeting 2023" article by Doug Devens, SmartTRAK's IT Product Director and Sr Analyst, Wound. Read the Article

Continue Reading
2 min read

Biosynthetic and Hybrid Xenograft Hernia Matrices Drive Growth: Q123 US Surgical Matrices Market Recap

By Doug Devens on 6/2/23 10:00 AM

Biosynthetic and hybrid xenograft hernia matrices continue to drive growth in hernia matrices, but breast matrices decline slightly in Q123.

The US Surgical Matrices Market gained +3.2% YoY according to SmartTRAK Financial Dashboard. AbbVie and Becton Dickinson (BD) remained in first and second positions, respectively, in the Q123 Surgical Matrices market. AbbVie had an -8.8% decline YoY, and in second place, BD gained +9.1% YoY to ...
 
Among the many topics covered in detail in our comprehensive Q123 US Surgical Matrices Market Recap* article:
  • Complete Q123 US Surgical Matrices Market Overview
  • SmartTRAK's Expert Market Analysis and Insights
  • All Company News, Revenues, Data, Charts and Shares
  • US Surgical Matrices Market Shuffles Leadership
  • US Breast Matrices: Holding Steady
  • US Hernia Repair Matrices Market: Another Solid Quarter
  • Q123 Clinical/Regulatory Highlights

The US Surgical Matrices Market grew in Q123 with more strength in the Hernia Matrices segment, due to the continued growth of biosynthetic matrices and TELA Bio’s OviTex as physicians use them for ...

Read the entire Q123 US Surgical Matrices Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below. Learn More about Subscribing to SmartTRAK
Continue Reading
2 min read

US Surgical Matrices Rebound: Q422 Market Recap

By Doug Devens on 3/17/23 9:30 AM

Breast Matrices rebound and grow modestly as AbbVie’s competitors take over market share. Biosynthetic and hybrid xenograft hernia matrices continue to drive growth in Hernia Matrices.

The US Surgical Matrices Market resumed its pre-pandemic trends, gaining +3.2% YoY according to SmartTRAK Financial Dashboard. AbbVie* and Becton Dickinson* (BD) remained in first and second positions, respectively, in the Q422 Surgical Matrices market. AbbVie held on to its leadership despite  a -4.4% YoY decline, while BD gained +6.1% YoY.

Among the many topics covered in detail in our comprehensive Q422 US Surgical Matrices Market Recap* are:

Continue Reading
2 min read

2023 US Hernia Matrices Outlook: Recent Trends and Potential Impact

By Doug Devens on 3/10/23 9:41 AM

SmartTRAK reviews recent trends in hernia matrices and their potential impact on the US Hernia Matrices Market, which is projected to reach $1.06B in 2023 according to SmartTRAK.

Incisional hernia procedures reached a peak in the mid-2000s, with a gradual decline as surgeons performed fewer abdominal procedures and researchers investigated new techniques for closure. While improved stitching for closure has had mixed results, surgeons are trying other new approaches to reduce incisional hernias such as MSI’s DuraMesh* and Deep Blue Medical’s T-line mesh* which are being used prophylactically.

In this Market Outlook article, we cover in detail:

  • Synthetic Matrices Poised for Slow Down
  • Alternatives to Synthetic Matrices Gaining Favor
    • Xenograft Matrices
    • Resorbable Meshes
    • Reinforced Xenograft Matrices
  • Expert Analysis and Conclusions
Continue Reading
2 min read

Continuing the Ascent: Q322 US Surgical Matrices Market Recap

By Doug Devens on 1/9/23 10:47 AM

Biosynthetic hernia matrices continue their ascent and Xenograft hernia matrices grow, thanks to TELA Bio.

As elective surgical procedures settle into pre-pandemic levels, the US Surgical Matrices Market resumed trends that had begun prior to Q322, gaining +2.4% YoY according to SmartTRAK Financial Dashboard. AbbVie* and Becton Dickinson* (BD) have been trading share positions in the last few quarters and now once again AbbVie has first place in the Q322 Surgical Matrices market despite of a -5.4% YoY decline, with BD In second place.

Among the many topics covered in detail in our comprehensive Q322 US Surgical Matrices Market Recap* are:

Continue Reading
2 min read

Trends in ADM Use from ASPS 2022

By Doug Devens on 12/20/22 9:30 AM

Surgeons are concerned about the cost of breast matrices in an increasingly restrictive environment, but alternatives may be on the horizon according to key discussions at the 2022 Plastic Surgery: The Meeting.

Breast matrices are used to cover breast implants in breast reconstruction and cosmetic breast surgeries. The matrices have become in effect standard of care in these surgeries, though they do not have FDA-approved indications for breast reconstruction or cosmetic breast surgeries. Moreover, the FDA has in recent years, issued warning letters and communications related to breast matrices. In 2015, the FDA issued warning letters reminding several companies that they did not ...

To read the complete "Trends in ADM Use from ASPS 2022" article by Doug Devens, SmartTRAK's Product Director/Sr. Analyst - Wound, in which  he shares observations from the ASPS sessions and the potential implications for the Breast Matrices Market, just click the following link.

Download the complete "Trends in ADM" Article

Continue Reading
2 min read

Leveling Out: Q222 US Surgical Matrices Market Recap

By Doug Devens on 9/5/22 9:30 AM

Surgical matrices revenue is flat while procedure volumes level out

With elective procedures in the United States mostly back at pre-pandemic levels, the US Surgical Matrices Market returned to what had been normal growth according to SmartTRAK Financial Dashboard. Becton Dickinson* (BD) grew to a 26.9% share, while AbbVie* slipped to second place.

Among the many topics covered in detail in our comprehensive Q222 US Surgical Matrices Market Recap* are:

Topics: Wound Care
Continue Reading
2 min read

Revenues on the Rise: Q122 US Surgical Matrices Market Recap

By Doug Devens on 6/17/22 12:34 PM

Surgical matrices procedures appear back to near pre-pandemic levels, with revenues on the rise

With elective procedures in the United States mostly back at pre-pandemic levels, the US Surgical Matrices Market returned to what had been normal growth in Q122, gaining +5.7% YoY according to SmartTRAK Financial Dashboard. AbbVie* continued to lead the Surgical Matrices Market, though it was approximately flat, while Becton Dickinson* (BD) grew strongly.

Among the many topics covered in detail in our comprehensive Q122 US Surgical Matrices Market Recap* are:

Topics: Wound Care
Continue Reading
2 min read

The Effect of Clinical Trial Investment On Hernia Matrices Revenues

By Doug Devens on 6/14/22 9:30 AM

SmartTRAK investigates recent trends in hernia repair clinical trials and how these trends relate to competition in the hernia repair market. Using a new SmartTRAK tool to analyze data in clinicaltrials.gov, SmartTRAK describes shifting trends in hernia repair research with company-sponsored studies and randomized controlled trials (RCTs)

Topics: Wound Care
Continue Reading
1 min read

2022 Outlook for US Breast Matrices: Recent Trends and Future Impact

By Doug Devens on 3/15/22 8:00 AM

SmartTRAK examines recent trends in breast implants and discusses their future impact on breast matrices.

Breast matrices, whether acellular dermal matrices (ADMs) or biosynthetics, have enabled improved outcomes in implant-based breast reconstruction and have contributed, in large part, to the revival of the prepectoral breast reconstruction technique. As the number of breast implant procedures has grown, so has the use of breast matrices. However, SmartTRAK believes the side effects and health consequences now associated with breast implants, while rare, will negatively impact breast implant usage and thus reduce the growth rate of breast matrices in 2022 and beyond.

In this informative Outlook article by Doug Devens, SmartTRAK's Product Director and Senior Editor, Wound, Doug covers:

  • The Relationship between Breast Surgery and ADM Usage
  • Trends in Implant Usage
  • Recent Concerns that May Affect Breast Implant Usage
  • The Future Outlook for 2022 and Beyond
Continue Reading
  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles